Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U, Hofmann MH, Friedbichler K, Baumgartinger R, Adam PJ, Solca F, Kraut N, Nguyen HM, Corey E, Liu G, Sprenger CC, Plymate SR, Bogenrieder T. Weyer-Czernilofsky U, et al. Among authors: solca f. Mol Cancer Ther. 2020 Apr;19(4):1059-1069. doi: 10.1158/1535-7163.MCT-19-0378. Epub 2020 Feb 13. Mol Cancer Ther. 2020. PMID: 32054790 Free PMC article.
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
Sini P, Gürtler U, Zahn SK, Baumann C, Rudolph D, Baumgartinger R, Strauss E, Haslinger C, Tontsch-Grunt U, Waizenegger IC, Solca F, Bader G, Zoephel A, Treu M, Reiser U, Garin-Chesa P, Boehmelt G, Kraut N, Quant J, Adolf GR. Sini P, et al. Among authors: solca f. Mol Cancer Ther. 2016 Oct;15(10):2388-2398. doi: 10.1158/1535-7163.MCT-16-0066. Epub 2016 Aug 5. Mol Cancer Ther. 2016. PMID: 27496137
Non-reproducible sequence artifacts in FFPE tissue: an experience report.
Ofner R, Ritter C, Ugurel S, Cerroni L, Stiller M, Bogenrieder T, Solca F, Schrama D, Becker JC. Ofner R, et al. Among authors: solca f. J Cancer Res Clin Oncol. 2017 Jul;143(7):1199-1207. doi: 10.1007/s00432-017-2399-1. Epub 2017 Mar 17. J Cancer Res Clin Oncol. 2017. PMID: 28314930
Afatinib is active in osteosarcoma in osteosarcoma cell lines.
Cruz-Ramos M, Zamudio-Cuevas Y, Medina-Luna D, Martínez-Flores K, Martínez-Nava G, Fernández-Torres J, López-Reyes A, Solca F. Cruz-Ramos M, et al. Among authors: solca f. J Cancer Res Clin Oncol. 2020 Jul;146(7):1693-1700. doi: 10.1007/s00432-020-03220-y. Epub 2020 Apr 24. J Cancer Res Clin Oncol. 2020. PMID: 32333142
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Wilding B, Scharn D, Böse D, Baum A, Santoro V, Chetta P, Schnitzer R, Botesteanu DA, Reiser C, Kornigg S, Knesl P, Hörmann A, Köferle A, Corcokovic M, Lieb S, Scholz G, Bruchhaus J, Spina M, Balla J, Peric-Simov B, Zimmer J, Mitzner S, Fett TN, Beran A, Lamarre L, Gerstberger T, Gerlach D, Bauer M, Bergner A, Schlattl A, Bader G, Treu M, Engelhardt H, Zahn S, Fuchs JE, Zuber J, Ettmayer P, Pearson M, Petronczki M, Kraut N, McConnell DB, Solca F, Neumüller RA. Wilding B, et al. Among authors: solca f. Nat Cancer. 2022 Jul;3(7):821-836. doi: 10.1038/s43018-022-00412-y. Epub 2022 Jul 26. Nat Cancer. 2022. PMID: 35883003
116 results